1. Search Result
Search Result
Results for "

4(Z),7(Z),10(Z)-Tridecatrienoic acid-d<sub>5</sub>

" in MedChemExpress (MCE) Product Catalog:

95

Inhibitors & Agonists

1

Biochemical Assay Reagents

28

Peptides

1

Inhibitory Antibodies

7

Natural
Products

13

Recombinant Proteins

18

Isotope-Labeled Compounds

3

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0041A

    Vasopressin Receptor Neurological Disease
    F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .
    F992 TFA
  • HY-P10218A

    MARCKS PKC Inflammation/Immunology Cancer
    MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide TFA
  • HY-P3462

    CGRP Receptor Metabolic Disease
    Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
    Cagrilintide
  • HY-165639S

    Isotope-Labeled Compounds Others
    4(Z),7(Z),10(Z)-Tridecatrienoic acid-d5 is deuterium labeled 4(Z),7(Z),10(Z)-Tridecatrienoic acid .
    4(Z),7(Z),10(Z)-Tridecatrienoic acid-d5
  • HY-RS13999

    Small Interfering RNA (siRNA) Others

    SUB1 Human Pre-designed siRNA Set A contains three designed siRNAs for SUB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SUB1 Human Pre-designed siRNA Set A
    SUB1 Human Pre-designed siRNA Set A
  • HY-146227

    Topoisomerase Apoptosis Cancer
    DNA topoisomerase II inhibitor 1 (compound 8ed) is a potent DNA topoisomerase II inhibitor. DNA topoisomerase II inhibitor 1 shows anti-proliferative activity. DNA topoisomerase II inhibitor 1 induces apoptosis and cell cycle arrest at sub G1 phase .
    DNA topoisomerase II inhibitor 1
  • HY-P0041

    Vasopressin Receptor Neurological Disease
    F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .
    F992
  • HY-P10218

    MARCKS PKC Inflammation/Immunology Cancer
    MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide
  • HY-P10200

    Bacterial Infection
    CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
    CP7-FP13-2
  • HY-P10318

    GLP Receptor Endocrinology
    SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
    SHR-2042
  • HY-P3462A

    CGRP Receptor Metabolic Disease
    Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
    Cagrilintide acetate
  • HY-P5161A

    GCGR Metabolic Disease
    FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .
    FC382K10W15 TFA
  • HY-P3143

    PD-1/PD-L1 Cancer
    BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50?of 7.68?nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST?and SPR assays, respectively.?BMSpep-57?facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57
  • HY-P3143A

    PD-1/PD-L1 Cancer
    BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68?nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57 hydrochloride
  • HY-P10271

    GLP Receptor Metabolic Disease
    RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
    RG7697
  • HY-P10341

    GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-113560

    Antibiotic Fungal Phospholipase Infection
    Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A2 (PLA2), which has antifungal activity .
    Plipastatin B1
  • HY-P1162

    SKF 100273

    Vasopressin Receptor Metabolic Disease
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin
  • HY-P4895

    Oxytocin Receptor Neurological Disease
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin
  • HY-P10272

    PTG-300

    Ferroportin Others
    Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
    Rusfertide
  • HY-10844S1

    PA-824-d<sub>5sub>; (S)-PA 824-d<sub>5sub>

    Antibiotic Bacterial Isotope-Labeled Compounds Infection Cancer
    Pretomanid-d5 is deuterated labeled Pretomanid (HY-10844). Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB). The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 μg/mL.
    Pretomanid-d5
  • HY-P10215

    Parasite Infection
    Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2 (compound 40) is a potent Plasmodium subtilisin-like protease 1 (SUB1) inhibitor. SUB1-IN-1 shows IC50 values of 12 nM and 10 nM against P. vivax and P. falciparum SUB1 (Pv- and PfSUB1), respectively .
    Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2
  • HY-P10563

    BHV-1100

    CD38 Cancer
    Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
    Noraramtide
  • HY-125833
    Alpha-Naphthoflavone
    5+ Cited Publications

    Cytochrome P450 Aryl Hydrocarbon Receptor Apoptosis Cancer
    Alpha-Naphthoflavone is an orally active flavonoid that is a potent, competitive inhibitor of aromatase< b>aromatase. < b > IC < sub > 50 < / sub > < / b > and < b > K < sub > I < / sub > < / b > value were 0.5 and 0.2 microns. Alpha-Naphthoflavone can inhibit cell proliferation and induce apoptosis .
    Alpha-Naphthoflavone
  • HY-17623S

    CJ-12420-d<sub>6sub>; RQ-00000004-d<sub>6sub>

    Proton Pump Na+/K+ ATPase Metabolic Disease
    Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan-d6
  • HY-W018392S

    MEHP-d<sub>4sub>; Phthalic acid mono-2-ethylhexyl ester-d<sub>4sub>

    Isotope-Labeled Compounds Metabolic Disease
    Mono-(2-ethylhexyl) phthalate-d4 is a deuterium labeled Mono-(2-ethylhexyl) phthalate (HY-W018392). Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .
    Mono-(2-ethylhexyl) phthalate-d4
  • HY-157440

    Amyloid-β Reactive Oxygen Species Cholinesterase (ChE) Neurological Disease
    AChE/Aβ-IN-3 (compound AM5) is a dual inhibitor of AChE and Amyloid-β aggregation with IC50<.sub> values of 1.29 and 4.93 μM, respectively. AChE/Aβ-IN-3 has antioxidant properties that scavenge ROS and restore their normal levels. AChE/Aβ-IN-3 can be used in the study of neurological diseases, such as Alzheimer's disease .
    AChE/Aβ-IN-3
  • HY-144290

    GSK-3 DYRK Neurological Disease
    ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation .
    ARN25068
  • HY-N7118

    Bacterial Antibiotic Infection Cancer
    Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) .
    Clindamycin hydrochloride monohydrate
  • HY-129946

    Dopamine Receptor Neurological Disease
    Dopamine D2 receptor antagonist-1 is a negative allosteric modulator (NAM) of the dopamine D2 receptor (D2R) with sub-mM affinity .
    Dopamine D2 receptor antagonist-1
  • HY-163129

    Apoptosis MMP Cancer
    BPU arrests cell cycle progression in the sub-G1 phase. BPU is an anticancer agent through inhibiting blood vessel formation in tumor tissues .
    BPU
  • HY-W050026S
    Phenylacetylglutamine-d5
    2 Publications Verification

    NSC 203800-d<sub>5sub>; Phenylacetyl-L-glutamine-d<sub>5sub>

    Endogenous Metabolite Isotope-Labeled Compounds Others
    Phenylacetylglutamine-d5 is the deuterium labeled Phenylacetylglutamine. Phenylacetylglutamine is a colonic microbial metabolite from amino acid fermentation[1].
    Phenylacetylglutamine-d5
  • HY-139823A

    Histone Methyltransferase Others
    PRMT5-IN-11 is a promising structure-dependent inhibition of the protein methyltransferase PRMT5:MEP50 complex in the (sub)micromolar range.
    PRMT5-IN-11
  • HY-144220

    NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3/AIM2-IN-1 is a thermal sepsis inhibitor with an < b > IC < sub > 50 < / sub > < / b > value of 3.136 ± 0.7667 μ M.
    NLRP3/AIM2-IN-1
  • HY-N11799

    3-O-Methylquercetin 4′-O-glucoside

    Others Others
    Neochilenin (3-O-Methylquercetin 4 '-O-glucoside) is a glycoside of 3-O-methylquercetin, which can be isolated from the sub-family Cereoideae (Cactaceae). .
    Neochilenin
  • HY-157728

    E1/E2/E3 Enzyme Inflammation/Immunology
    ML307 is a potent, sub-micromolar, first-in-class Ubc13 enzyme activity inhibitor with an IC50 of 781 nM. ML307 has the potential for immunomodulation and inflammation research .
    ML307
  • HY-119095

    Neurokinin Receptor Neurological Disease Endocrinology
    L-741671 is a selective and brain-permeable antagonist of neurokininl (hNKI) receptor, with Kis of 64 nM, 0.03 nM and 0.7 nM in rat, human and ferret, respectively .
    L-741671
  • HY-111258

    Prostaglandin Receptor Neurological Disease Inflammation/Immunology
    GSK345931A is an EP1 receptor antagonist. GSK345931A shows measurable CNS penetration in the mouse and rat and potent analgesic efficacy in acute and sub-chronic models of inflammatory pain .
    GSK345931A
  • HY-138616S

    2'-Deoxyguanosine-5'-triphosphate-<sub>15subN<sub>5sub dilithium

    Isotope-Labeled Compounds DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Infection Cancer
    dGTP- 15N5 (2'-Deoxyguanosine-5'-triphosphate- 15N5) dilithium is 15N labeled dGTP (HY-138616). dGTP (2'-Deoxyguanosine-5'-triphosphate), a guanosine nucleotide, can be used in deoxyribonucleic acid synthesis. Guanosine nucleotides (GDP, GTP, dGDP, and dGTP) are highly susceptible to oxidative damage to 8-oxo-GDP (8-O-GDP), 8-O-dGTP, 8-O-GTP, and 8-O-dGTP.
    dGTP-15N5 dilithium
  • HY-138616S2

    2'-Deoxyguanosine-5'-triphosphate-15N<sub>5sub>,d<sub>14sub> dilithium

    Isotope-Labeled Compounds DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Infection Cancer
    dGTP- 15N5,d14 (2'-Deoxyguanosine-5'-triphosphate- 15N5,d14) dilithium is deuterium and 15N labeled dGTP (HY-138616). dGTP (2'-Deoxyguanosine-5'-triphosphate), a guanosine nucleotide, can be used in deoxyribonucleic acid synthesis. Guanosine nucleotides (GDP, GTP, dGDP, and dGTP) are highly susceptible to oxidative damage to 8-oxo-GDP (8-O-GDP), 8-O-dGTP, 8-O-GTP, and 8-O-dGTP.
    dGTP-15N5,d14 dilithium
  • HY-P3426

    Beta-secretase Cancer
    BACE1-IN-10 is a potent BACE1 Inhibitor. BACE1-IN-10 shows sub-micromolar activity against recombinant BACE1 (rBACE1) .
    BACE1-IN-10
  • HY-N7118R

    Bacterial Antibiotic Infection Cancer
    Clindamycin (hydrochloride monohydrate) (Standard) is the analytical standard of Clindamycin (hydrochloride monohydrate). This product is intended for research and analytical applications. Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) .
    Clindamycin (hydrochloride monohydrate) (Standard)
  • HY-P5524

    Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid

    NOD-like Receptor (NLR) Others
    C12-iE-DAP (Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid) is a biological active peptide. (a lauroyl (C12) group to the glutamic residue of iE-DAP , NOD1 agonist)
    C12-iE-DAP
  • HY-B0167S1

    2-Hydroxybenzoic acid-13C<sub>6sub>

    Autophagy Apoptosis COX Mitophagy Endogenous Metabolite Isotope-Labeled Compounds Inflammation/Immunology Cancer
    Salicylic acid- 13C6 is the 13C-labeled Salicylic acid (HY-B0167). Salicylic acid is a precursor to and a metabolite of Aspirin (HY-14654), can inhibit cyclo-oxygenase-2 (COX-2) activity[1][2].
    Salicylic acid-13C6
  • HY-B1455
    Clindamycin
    5+ Cited Publications

    Bacterial Antibiotic Parasite Infection Cancer
    Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin
  • HY-111673

    8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium

    PKA Phosphodiesterase (PDE) Inflammation/Immunology
    8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA) with an IC50 of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC50 s of 24 and 25 μM, respectively. 8-CPT-Cyclic AMP sodium is a very high affinity for Epac and is a potent Epac activator .
    8-CPT-Cyclic AMP sodium
  • HY-138616S4

    2'-Deoxyguanosine-5'-triphosphate-13C<sub>10sub>,15N<sub>5sub> dilithium

    Isotope-Labeled Compounds DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Infection Cancer
    dGTP- 13C10, 15N5 (2'-Deoxyguanosine-5'-triphosphate- 13C10, 15N5) dilithium is 13C and 15N-labeled dGTP (HY-138616). dGTP (2'-Deoxyguanosine-5'-triphosphate), a guanosine nucleotide, can be used in deoxyribonucleic acid synthesis. Guanosine nucleotides (GDP, GTP, dGDP, and dGTP) are highly susceptible to oxidative damage to 8-oxo-GDP (8-O-GDP), 8-O-dGTP, 8-O-GTP, and 8-O-dGTP.
    dGTP-13C10,15N5 dilithium
  • HY-U00037

    PLA 725

    Phospholipase Inflammation/Immunology
    Ecopladib is a sub-micromolar inhibitor of cytosolic phospholipase A2α (cPLA2α), with IC50s of 0.15 μM and 0.11 μM in the GLU micelle and rat whole blood assays, respectively.
    Ecopladib
  • HY-111192
    IPR-803
    2 Publications Verification

    Ser/Thr Protease Cancer
    IPR-803 is a potent inhibitor of the uPAR·uPA protein-protein interaction (PPI). IPR-803 binds directly to uPAR with sub-micromolar affinity. IPR-803 displays anti-tumor activity .
    IPR-803
  • HY-144238

    PGE synthase Inflammation/Immunology
    MPGES-1 is considered as a promising therapeutic target of the next generation anti-inflammatory drugs in the research of inflammatory diseases. The < b > IC < sub > 50 < / sub > < / b > value of mPGES1-IN-6 is 0.03 μ M。
    mPGES1-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: